227 related articles for article (PubMed ID: 36989892)
1. Thymosin alpha 1 restores the immune homeostasis in lymphocytes during Post-Acute sequelae of SARS-CoV-2 infection.
Minutolo A; Petrone V; Fanelli M; Maracchioni C; Giudice M; Teti E; Coppola L; Sorace C; Iannetta M; Tony Miele M; Bernardini S; Mastino A; Sinibaldi Vallebona P; Balestrieri E; Andreoni M; Sarmati L; Grelli S; Garaci E; Matteucci C
Int Immunopharmacol; 2023 May; 118():110055. PubMed ID: 36989892
[TBL] [Abstract][Full Text] [Related]
2. Novel evidence of Thymosin α1 immunomodulatory properties in SARS-CoV-2 infection: Effect on innate inflammatory response in a peripheral blood mononuclear cell-based in vitro model.
Ricci D; Etna MP; Severa M; Fiore S; Rizzo F; Iannetta M; Andreoni M; Balducci S; Stefanelli P; Palamara AT; Coccia EM
Int Immunopharmacol; 2023 Apr; 117():109996. PubMed ID: 36933449
[TBL] [Abstract][Full Text] [Related]
3. Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients.
Wang Z; Chen J; Zhu C; Liu L; Qi T; Shen Y; Zhang Y; Xu L; Li T; Qian Z; Steinhart CR; Lu H
Front Immunol; 2021; 12():568789. PubMed ID: 34149679
[TBL] [Abstract][Full Text] [Related]
4. Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells.
Liu Y; Pan Y; Hu Z; Wu M; Wang C; Feng Z; Mao C; Tan Y; Liu Y; Chen L; Li M; Wang G; Yuan Z; Diao B; Wu Y; Chen Y
Clin Infect Dis; 2020 Nov; 71(16):2150-2157. PubMed ID: 32442287
[TBL] [Abstract][Full Text] [Related]
5. Thymosin alpha 1 - Reimagine its broader applications in the immuno-oncology era.
Mao L
Int Immunopharmacol; 2023 Apr; 117():109952. PubMed ID: 36871535
[TBL] [Abstract][Full Text] [Related]
6. Gender-associated difference following COVID-19 virus infection: Implications for thymosin alpha-1 therapy.
Li X; Liu L; Yang Y; Yang X; Wang C; Li Y; Ge Y; Shi Y; Lv P; Zhou H; Luo P; Huang S
Int Immunopharmacol; 2021 Jan; 90():107022. PubMed ID: 33160854
[TBL] [Abstract][Full Text] [Related]
7. Thymosin α1 modulated the immune landscape of COVID-19 patients revealed by single-cell RNA and TCR sequencing.
Bai H; Liang L; Qi X; Xu Y; Liu Y; Ren D; Cai Z; Mao W; Wang X; Qin H; Hu F; Shi B
Int Immunopharmacol; 2023 Nov; 124(Pt B):110983. PubMed ID: 37769533
[TBL] [Abstract][Full Text] [Related]
8. Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients.
Matteucci C; Minutolo A; Balestrieri E; Petrone V; Fanelli M; Malagnino V; Ianetta M; Giovinazzo A; Barreca F; Di Cesare S; De Marco P; Miele MT; Toschi N; Mastino A; Sinibaldi Vallebona P; Bernardini S; Rogliani P; Sarmati L; Andreoni M; Grelli S; Garaci E
Open Forum Infect Dis; 2021 Jan; 8(1):ofaa588. PubMed ID: 33506065
[TBL] [Abstract][Full Text] [Related]
9. Immune mechanisms underlying COVID-19 pathology and post-acute sequelae of SARS-CoV-2 infection (PASC).
Mohandas S; Jagannathan P; Henrich TJ; Sherif ZA; Bime C; Quinlan E; Portman MA; Gennaro M; Rehman J;
Elife; 2023 May; 12():. PubMed ID: 37233729
[TBL] [Abstract][Full Text] [Related]
10. Tissue injury and leukocyte changes in post-acute sequelae of SARS-CoV-2: review of 2833 post-acute patient outcomes per immune dysregulation and microbial translocation in long COVID.
Islam MS; Wang Z; Abdel-Mohsen M; Chen X; Montaner LJ
J Leukoc Biol; 2023 Mar; 113(3):236-254. PubMed ID: 36807444
[TBL] [Abstract][Full Text] [Related]
11. A Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection.
Shehadeh F; Benitez G; Mylona EK; Tran QL; Tsikala-Vafea M; Atalla E; Kaczynski M; Mylonakis E
J Infect Dis; 2023 Jan; 227(2):226-235. PubMed ID: 36056913
[TBL] [Abstract][Full Text] [Related]
12. The Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 infection.
Moghimi N; Di Napoli M; Biller J; Siegler JE; Shekhar R; McCullough LD; Harkins MS; Hong E; Alaouieh DA; Mansueto G; Divani AA
Curr Neurol Neurosci Rep; 2021 Jun; 21(9):44. PubMed ID: 34181102
[TBL] [Abstract][Full Text] [Related]
13. Single-cell RNA sequencing reveals characteristics of myeloid cells in post-acute sequelae of SARS-CoV-2 patients with persistent respiratory symptoms.
Yoon H; Dean LS; Jiyarom B; Khadka VS; Deng Y; Nerurkar VR; Chow DC; Shikuma CM; Devendra G; Koh Y; Park J
Front Immunol; 2023; 14():1268510. PubMed ID: 38259488
[TBL] [Abstract][Full Text] [Related]
14. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms.
Peluso MJ; Deitchman AN; Torres L; Iyer NS; Munter SE; Nixon CC; Donatelli J; Thanh C; Takahashi S; Hakim J; Turcios K; Janson O; Hoh R; Tai V; Hernandez Y; Fehrman EA; Spinelli MA; Gandhi M; Trinh L; Wrin T; Petropoulos CJ; Aweeka FT; Rodriguez-Barraquer I; Kelly JD; Martin JN; Deeks SG; Greenhouse B; Rutishauser RL; Henrich TJ
Cell Rep; 2021 Aug; 36(6):109518. PubMed ID: 34358460
[TBL] [Abstract][Full Text] [Related]
15. Pathogenic mechanisms of post-acute sequelae of SARS-CoV-2 infection (PASC).
Sherif ZA; Gomez CR; Connors TJ; Henrich TJ; Reeves WB;
Elife; 2023 Mar; 12():. PubMed ID: 36947108
[TBL] [Abstract][Full Text] [Related]
16. Thymalfasin for the treatment of chronic hepatitis B.
Chien RN; Liaw YF
Expert Rev Anti Infect Ther; 2004 Feb; 2(1):9-16. PubMed ID: 15482167
[TBL] [Abstract][Full Text] [Related]
17. Neuro-PASC is characterized by enhanced CD4+ and diminished CD8+ T cell responses to SARS-CoV-2 Nucleocapsid protein.
Visvabharathy L; Hanson BA; Orban ZS; Lim PH; Palacio NM; Jimenez M; Clark JR; Graham EL; Liotta EM; Tachas G; Penaloza-MacMaster P; Koralnik IJ
Front Immunol; 2023; 14():1155770. PubMed ID: 37313412
[TBL] [Abstract][Full Text] [Related]
18. Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection.
Ryan FJ; Hope CM; Masavuli MG; Lynn MA; Mekonnen ZA; Yeow AEL; Garcia-Valtanen P; Al-Delfi Z; Gummow J; Ferguson C; O'Connor S; Reddi BAJ; Hissaria P; Shaw D; Kok-Lim C; Gleadle JM; Beard MR; Barry SC; Grubor-Bauk B; Lynn DJ
BMC Med; 2022 Jan; 20(1):26. PubMed ID: 35027067
[TBL] [Abstract][Full Text] [Related]
19. Thymosin alpha 1 treatment for patients with sepsis.
Pei F; Guan X; Wu J
Expert Opin Biol Ther; 2018 Jul; 18(sup1):71-76. PubMed ID: 30063866
[TBL] [Abstract][Full Text] [Related]
20. Early immune factors associated with the development of post-acute sequelae of SARS-CoV-2 infection in hospitalized and non-hospitalized individuals.
Leung JM; Wu MJ; Kheradpour P; Chen C; Drake KA; Tong G; Ridaura VK; Zisser HC; Conrad WA; Hudson N; Allen J; Welberry C; Parsy-Kowalska C; Macdonald I; Tapson VF; Moy JN; deFilippi CR; Rosas IO; Basit M; Krishnan JA; Parthasarathy S; Prabhakar BS; Salvatore M; Kim CC
Front Immunol; 2024; 15():1348041. PubMed ID: 38318183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
